Cargando…

Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer

PURPOSE: Chromosomal copy number aberrations (CNAs) are a hallmark of bladder cancer and a useful target for diagnostic explorations. Here we constructed a low-coverage whole-genome sequencing method for the detection of CNAs in urine sediment DNA from patients with bladder cancer. PATIENTS AND METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Yun-xi, Yang, Xu, Lin, Sheng, Xu, Ya-wen, Zhu, Shan-wen, Fan, Dong-mei, Zhao, Min, Zhang, Yuan-bin, Yang, Xue-xi, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924115/
https://www.ncbi.nlm.nih.gov/pubmed/33664588
http://dx.doi.org/10.2147/CMAR.S295675
_version_ 1783659024392126464
author Cai, Yun-xi
Yang, Xu
Lin, Sheng
Xu, Ya-wen
Zhu, Shan-wen
Fan, Dong-mei
Zhao, Min
Zhang, Yuan-bin
Yang, Xue-xi
Li, Xin
author_facet Cai, Yun-xi
Yang, Xu
Lin, Sheng
Xu, Ya-wen
Zhu, Shan-wen
Fan, Dong-mei
Zhao, Min
Zhang, Yuan-bin
Yang, Xue-xi
Li, Xin
author_sort Cai, Yun-xi
collection PubMed
description PURPOSE: Chromosomal copy number aberrations (CNAs) are a hallmark of bladder cancer and a useful target for diagnostic explorations. Here we constructed a low-coverage whole-genome sequencing method for the detection of CNAs in urine sediment DNA from patients with bladder cancer. PATIENTS AND METHODS: We conducted a prospective study using urine sediment samples from 65 patients with bladder tumors, including 54 patients with bladder cancer and 11 patients with benign bladder tumors. Forty-three healthy individuals were included as normal controls. DNA was extracted from urine sediments and analyzed by low-coverage whole-genome sequencing to compare differences in CNAs among these three groups. CNAs are defined by arbitrary R values (normal range ± 2). When these values exceed ± 0.2 of normal range, gain/duplication or loss/deletion are suspected. RESULTS: With this method, CNAs were detected in 39 of 51 patients with bladder cancer, 2 of 10 patients with benign bladder tumors, and 8 of 39 normal controls. The lengths of DNA deletion and duplication were significantly larger in patients with bladder cancer than in patients with benign tumors or normal controls (P < 0.05). Bladder cancer duplicate CNAs mainly occurred on chromosomes 1q, 5p, 6p, 7p, 8q, and 13q, while deletions mainly occurred on 2q, 8p, 9q, 9p, and 11p. Those regions contained bladder cancer tumor-related genes, such as STK3, COX6C, SPAG1, CDKAL1, C9orf53, CDKN2A, CDKN2B, MIR31, and IFNA1. The number of CNAs detected in urine sediment DNA during the follow-up period was significantly reduced. CONCLUSION: Our sequencing method is highly sensitive and can detect a minimal chromosome repeat/microdeletion change of 0.15 Mb. The use of 0.1~0.3× low-coverage whole-genome sequencing can be used to detect bladder cancer CNAs in urine sediment DNA. This method provides a promising method for noninvasive diagnosis of bladder cancer, but still needs further verification in a larger sample size.
format Online
Article
Text
id pubmed-7924115
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79241152021-03-03 Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer Cai, Yun-xi Yang, Xu Lin, Sheng Xu, Ya-wen Zhu, Shan-wen Fan, Dong-mei Zhao, Min Zhang, Yuan-bin Yang, Xue-xi Li, Xin Cancer Manag Res Original Research PURPOSE: Chromosomal copy number aberrations (CNAs) are a hallmark of bladder cancer and a useful target for diagnostic explorations. Here we constructed a low-coverage whole-genome sequencing method for the detection of CNAs in urine sediment DNA from patients with bladder cancer. PATIENTS AND METHODS: We conducted a prospective study using urine sediment samples from 65 patients with bladder tumors, including 54 patients with bladder cancer and 11 patients with benign bladder tumors. Forty-three healthy individuals were included as normal controls. DNA was extracted from urine sediments and analyzed by low-coverage whole-genome sequencing to compare differences in CNAs among these three groups. CNAs are defined by arbitrary R values (normal range ± 2). When these values exceed ± 0.2 of normal range, gain/duplication or loss/deletion are suspected. RESULTS: With this method, CNAs were detected in 39 of 51 patients with bladder cancer, 2 of 10 patients with benign bladder tumors, and 8 of 39 normal controls. The lengths of DNA deletion and duplication were significantly larger in patients with bladder cancer than in patients with benign tumors or normal controls (P < 0.05). Bladder cancer duplicate CNAs mainly occurred on chromosomes 1q, 5p, 6p, 7p, 8q, and 13q, while deletions mainly occurred on 2q, 8p, 9q, 9p, and 11p. Those regions contained bladder cancer tumor-related genes, such as STK3, COX6C, SPAG1, CDKAL1, C9orf53, CDKN2A, CDKN2B, MIR31, and IFNA1. The number of CNAs detected in urine sediment DNA during the follow-up period was significantly reduced. CONCLUSION: Our sequencing method is highly sensitive and can detect a minimal chromosome repeat/microdeletion change of 0.15 Mb. The use of 0.1~0.3× low-coverage whole-genome sequencing can be used to detect bladder cancer CNAs in urine sediment DNA. This method provides a promising method for noninvasive diagnosis of bladder cancer, but still needs further verification in a larger sample size. Dove 2021-02-26 /pmc/articles/PMC7924115/ /pubmed/33664588 http://dx.doi.org/10.2147/CMAR.S295675 Text en © 2021 Cai et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Cai, Yun-xi
Yang, Xu
Lin, Sheng
Xu, Ya-wen
Zhu, Shan-wen
Fan, Dong-mei
Zhao, Min
Zhang, Yuan-bin
Yang, Xue-xi
Li, Xin
Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer
title Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer
title_full Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer
title_fullStr Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer
title_full_unstemmed Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer
title_short Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer
title_sort low-coverage sequencing of urine sediment dna for detection of copy number aberrations in bladder cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924115/
https://www.ncbi.nlm.nih.gov/pubmed/33664588
http://dx.doi.org/10.2147/CMAR.S295675
work_keys_str_mv AT caiyunxi lowcoveragesequencingofurinesedimentdnafordetectionofcopynumberaberrationsinbladdercancer
AT yangxu lowcoveragesequencingofurinesedimentdnafordetectionofcopynumberaberrationsinbladdercancer
AT linsheng lowcoveragesequencingofurinesedimentdnafordetectionofcopynumberaberrationsinbladdercancer
AT xuyawen lowcoveragesequencingofurinesedimentdnafordetectionofcopynumberaberrationsinbladdercancer
AT zhushanwen lowcoveragesequencingofurinesedimentdnafordetectionofcopynumberaberrationsinbladdercancer
AT fandongmei lowcoveragesequencingofurinesedimentdnafordetectionofcopynumberaberrationsinbladdercancer
AT zhaomin lowcoveragesequencingofurinesedimentdnafordetectionofcopynumberaberrationsinbladdercancer
AT zhangyuanbin lowcoveragesequencingofurinesedimentdnafordetectionofcopynumberaberrationsinbladdercancer
AT yangxuexi lowcoveragesequencingofurinesedimentdnafordetectionofcopynumberaberrationsinbladdercancer
AT lixin lowcoveragesequencingofurinesedimentdnafordetectionofcopynumberaberrationsinbladdercancer